TCGA-E9-A1RC-01A-11R-A157-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- E2F_TARGETS+0.290
- GLYCOLYSIS+0.250
- DNA_REPAIR+0.240
- MITOTIC_SPINDLE+0.230
- ESTROGEN_RESPONSE_EARLY+0.220
- G2M_CHECKPOINT+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.210
- MYC_TARGETS_V1+0.200
- SPERMATOGENESIS+0.150
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.550
- INTERFERON_ALPHA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- KRAS_SIGNALING_UP-0.390
- INFLAMMATORY_RESPONSE-0.370
- IL2_STAT5_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- COAGULATION-0.290
- CHOLESTEROL_HOMEOSTASIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.883 |
| 2 | TCGA-C8-A26Z-01A-11R-A16F-07 | — | B | 0.833 |
| 3 | MBCProject_6127_T1_RNA | — | B | 0.833 |
| 4 | TCGA-E2-A154-01A-11R-A115-07 | — | B | 0.831 |
| 5 | b09c5d28-8a02-4343-b678-07cbf351ed44 | — | — | 0.831 |
| 6 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.829 |
| 7 | GSM5359416 | — | — | 0.819 |
| 8 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.817 |
| 9 | TCGA-AR-A2LK-01A-11R-A180-07 | — | B | 0.815 |
| 10 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |